SGCB and heart failure: The possibility of expanding the use of vericiguat to a broader range of patients is presently investigated by the VICTOR study, a phase III randomized, placebo-controlled clinical trial, on the effectiveness and safety of the sGC stimulator vericiguat/MK-1242 in adults diagnosed with HFrEF who have not been hospitalized for heart failure recently or required outpatient intravenous diuretics [48].